AI Article Synopsis
- Mantle cell lymphoma (MCL) is an incurable B-cell lymphoma and pirtobrutinib has shown promising results in patients who have already undergone multiple treatments, but real-world data is limited.
- A study analyzed 10 MCL patients who received pirtobrutinib from a compassionate use program, revealing a 67% best overall response rate after an average of three previous treatments.
- The findings indicated that pirtobrutinib is a safe and effective treatment option for these patients, with positive outcomes and no new safety concerns reported.
Article Abstract
Background: Mantle cell lymphoma (MCL) is a type of B-cell lymphoma that is currently incurable. Pirtobrutinib shows promising response rates in heavily pretreated MCL patients according to the approval study, but the real-world data are scarce.
Methods: In this study, we retrospectively analyzed the efficacy and safety profile of pirtobrutinib in 10 relapsed/refractory MCL patients from compassionate use program (CUP).
Results: On average, the patients underwent three lines of systemic therapy prior to pirtobrutinib and were predominantly BTKi exposed (9/10). The best overall response rate (BORR) was 67%. In a median follow-up of 8.6 months, the mean duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were not reached. No new safety signals were documented.
Conclusions: In summary, pirtobrutinib represented a safe and effective treatment option in a small real-world population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11106640 | PMC |
| http://dx.doi.org/10.1002/cam4.7289 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!